Net Income

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

Apparel giant Oxford Industries posts a fiscal year loss after a major writedown, but sees a path to profit driven by a Tommy Bahama resurgence.

Keurig Dr Pepper's upcoming Q1 results are more than just numbers; they're the first look at a company on the brink of a massive transformation.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

As GLP-1 drug demand soars, Nordic Cold Chain Solutions launches a new lab to solve the complex puzzle of keeping these sensitive medicines safe.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

A Florida firm says its 15-year study proves 'Hypergrowth Stocks' are a unique asset class. But can a 40% growth metric truly redefine investing?

Cocoa prices are falling, but your chocolate bar costs more. Discover why consumers are embracing this shift by reaching for premium, pricier treats.

An Austin-based firm's rapid expansion to 150 partners shows how CE/CME is moving from conference halls to podcasts, apps, and on-demand platforms.

With $1B in funding and a new virtual cell model, Xaira Therapeutics hires a top dealmaker to turn its AI prowess into pharma partnerships.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

WeInfuse launches InfuseTrack, a new platform to end the chaos of manual equipment management and boost safety and compliance in infusion centers.

AI-powered deepfakes bypass tech defenses to exploit human trust, costing firms millions. New research reveals how to fight this emerging cyber threat.

A new wave of drug-free hair restoration combines ancient botanicals with FDA-cleared light therapy, challenging the chemical-reliant status quo.

A troubled mortgage firm is paying shareholders while under a trade ban, revealing a portfolio in distress and raising red flags for Canada's lending sector.

Amid economic uncertainty, TruStage reports over $6.1B in revenue, climbs life insurance ranks, and deepens its fintech and community investments.

Amidst a sea of single-function apps, CWILL's integrated AI platform for DTC brands promises to simplify operations and redefine the customer journey.

With a 100% residency match, BayCare is doubling its medical training program, creating a vital pipeline of physicians to serve a rapidly growing Florida.

A new deal with a top European insurer validates Global AI's advanced platform in a high-stakes market, but can its financials keep pace with its tech?

As the 2026 season begins, MLB reaffirms its historic USO alliance, translating the spirit of baseball into tangible support for military communities.